Transfusing activated platelets can increase the number of transfusions required and thus lead to additional costs compared with transfusing resting platelets.
Bill Dubiel, CEO, LightIntegra
Bill Dubiel is the president and CEO of LightIntegra Technologies, bringing more than 30 years of health care experience with his last 10 years spent specifically helping medical device startups through commercial buildout and product launch. Previously, Bill was chief commercial officer at PGDx and CyVek and was responsible for building a commercial organization to launch novel products into the global market. Bill also held executive sales, marketing, and service leadership positions at Ventana, Roche, Bayer, and Chiron Diagnostics. Bill holds a BS from Rutgers University and an MBA from Phoenix University.